Therapeutic improves liver function, insulin resistance in NASH phase 2b trial

Interim analysis results from a phase 2b trial of MSDC-062K for patients with nonalcoholic steatohepatitis and fibrosis showed significant improvements in liver function and insulin resistance at 6 months compared with baseline, according to a press release from Cirius Therapeutics.
MSDC-0602K is a second-generation insulin sensitizer designed to selectively modulate the mitochondrial pyruvate carrier (MPC).
“The interim results from the Emminence trial, the largest phase 2b clinical trial to include paired biopsies ever conducted in NASH, are compelling,” Stephen Harrison, MD,

Source link

Related posts

Little difference between fecal incontinence therapies for women


Advanced neoplasia risk differs between diminutive, small adenoma at baseline


Stress ulcer prophylaxis with proton pump inhibitors or histamine 2 receptor antagonists in critically ill adults – a meta-analysis of randomized controlled trials with trial sequential analysis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy